Safety and tolerability of ACZ885 (Canakinumab) in patients with gout The purpose of this third extension study is to provide additional long-term safety and tolerability data of canakinumab over an 18-month time period on patients who have completed the extension studi...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, placebo-controlled study to assess the safety, tolerability, and efficacy of oral RSV604 in healthy adults experimentally infected with respiratory syncytial virus - To evaluate the antiviral activity of RSV604, given orally, on nasal RSV load, as measured by RT-PCR, in healthy adults experimentally inoculated with a challenge virus of RSV. - To evaluate the s...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with docetaxel in second-line treatment of patients with advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC) To compare overall survival between the ASA404 plus docetaxel group and the placebo plus docetaxel group

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis assessing different doses and dose regimens Efficacy of secukinumab over 52 weeks based on PASI, in two different doses and two treatment regimens (fixed interval vs personalized treatment), in subjects with moderate to severe chronic plaque-ty...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An 8 week, double-blind, randomized, parallel group, active-controlled study to evaluate the efficacy and safety of the combination of Aliskiren /Amlodipine / HCTZ in patients with moderate to severe hypertension The primary objective of the study is to demonstrate that a once daily dosing regimen of the triple combination of aliskiren/amlodipine/HCTZ is superior to the double combinations of aliskiren/amlodip...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A randomized, double-blind, double-dummy, active controlled study of ACZ885 (canakinumab) on the treatment and prevention of gout flares in patients with frequent flares, for whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective The two co-primary objectives of this study are: • To confirm that canakinumab 150 mg s.c. is superior to triamcinolone acetonide 40 mg i.m. with respect to patient’s assessment of gout pain intensity...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An open label, stratified, single-arm phase II study of RAD001 in patients with advanced pancreatic neuroendocrine tumor (NET) after failure of cytotoxic chemotherapy To determine the objective response rate (ORR) (including complete response and partial response) of RAD001 10 mg po qd monotherapy in patients with advanced (unresectable or metastatic) pancreatic NE...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study of everolimus plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced neuroendocrine cancer of gastrointestinal or lung origin. Klinické hodnocení everolimu plus nejlepší podpůrná léčba versus placebo plus nejlepší podpůrná léčba v léčbě pacientů s pokročilými neuroendokrinními nádory gastrointestinálního nebo plicního původu Determinate whether treatment with everolimus plus best supportive care prolongs PFS compared to placebo plus best supportive care in patients with advanced NET of GI or lung origin

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An interventional study of PDR001 in adult patients with nasopharyngeal carcinoma (NPC) who have progressed on standard treatment To assess the efficacy of PDR001 versus investigator’s choice of chemotherapy in patients with moderately differentiated / undifferentiated locally advanced recurrent or metastatic NPC who progressed...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A facilitated access program to provide Everolimus (RAD) for maintenance for patients completing therapy in RAD trials in solid organ transplantation • To facilitate the management of patients on maintenance immunosuppression therapy who are completing everolimus trials, • To provide everolimus maintenance therapy through this access program and ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune